Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update

Jyong Biotech Ltd. (NASDAQ:MENS) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 208,547 shares, a drop of 36.2% from the June 15th total of 327,052 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 188,004 shares, the days-to-cover ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Jyong Biotech currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in Jyong Biotech in the 3rd quarter valued at about $512,000. Jane Street Group LLC bought a new position in Jyong Biotech during the fourth quarter worth about $275,000. Geode Capital Management LLC increased its stake in shares of Jyong Biotech by 19.6% in the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Jyong Biotech in the third quarter valued at approximately $67,000. Finally, Man Group plc purchased a new stake in shares of Jyong Biotech during the 4th quarter valued at approximately $56,000.

Jyong Biotech Stock Down 1.7%

MENS traded down $0.04 during midday trading on Friday, reaching $2.26. The company had a trading volume of 53,163 shares, compared to its average volume of 109,600. Jyong Biotech has a 12-month low of $1.43 and a 12-month high of $67.00. The business has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $2.32.

Jyong Biotech (NASDAQ:MENS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.